Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04968106 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Study acronym: TORNADO
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 52 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 4 to 3
    • Primary completion date changed from estimate of Mar 2026 to Aug 6, 2025
    • Study completion date: Oct 2027 to Apr 2028
    v10
  3. Primary completion date: Mar 2025 to Mar 2026v9
  4. Start date: Mar 23, 2022 to Dec 7, 2022
    • Eligibility criteria expanded, about 15 words
    • Site details revised at 2 of 4 sites
    v8
  5. Trial status: Not Yet Recruiting to Recruitingv7 Show 5 more changesShow less
    • Primary completion date: Jun 2024 to Mar 2025
    • Study completion date: Dec 2024 to Oct 2027
    • Start date changed from estimate of Jun 1, 2022 to Mar 23, 2022
    • Site details revised at 4 of 4 sites
    • Study title shortened, about 1 word
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Apr 1, 2022 to Jun 1, 2022
    • Primary completion date: Apr 2024 to Jun 2024
    • Study completion date: Oct 2024 to Dec 2024
    v6
  2. Start date: Feb 1, 2022 to Apr 1, 2022
    • Primary completion date: Mar 2024 to Apr 2024
    • Study completion date: Sep 2024 to Oct 2024
    v5
  3. Start date: Nov 1, 2021 to Feb 1, 2022v4
  4. Start date: Sep 2021 to Nov 1, 2021v3
  5. Study title shortened, about 4 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Bergonié
40 trials monitored
See 1 trial at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Trial Details
NCT Number NCT04968106
Lead Sponsor Institut Bergonié
Collaborators: Incyte Biosciences International Sàrl
Conditions
(from sponsor)		 Resectable Sarcoma
Related terms Sarcoma
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov